PCP
RARE icon

Proficio Capital Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Proficio Capital Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-106
Closed -$7K – 1196
2019
Q2 		$7K Sell
106
-7
-6% -$446 ﹤0.01% 1092
2019
Q1 		$8K Buy
+113
New +$6.46K ﹤0.01% 963

Other funds holding RARE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Proficio Capital Partners's RARE Position: Q3 2019 in Review

Proficio Capital Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2019, closing a stake of 106 shares — an estimated $7K sold.

Proficio Capital Partners first reported a position in RARE in Q1 2019 and held it in 2 quarters. The position peaked at $8K in Q1 2019. 172 funds tracked by Wall St. Rank hold RARE as of Q3 2019.

  • Proficio Capital Partners reported no remaining Ultragenyx Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 106 Ultragenyx Pharmaceutical shares in Q3 2019, an estimated $7K.
  • Proficio Capital Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and held it in 2 quarters.
  • Proficio Capital Partners's Ultragenyx Pharmaceutical position peaked at $8K in Q1 2019.
  • 172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.